Hiroshi Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Ishikawa has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Motoi Nomura
Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi, 329-0412, Japan
3 shared publications - Taisuke Kuroda
Clinical Veterinary Medicine Division, Equine Research Institute Japan Racing Association Shimotsuke Japan
3 shared publications H Mita
1 shared publicationHiroshi Ishikawa
1 shared publicationHiroshi Mita
Clinical Veterinary Medicine Division Equine Research Institute, Japan Racing Association Shimotsuke Japan
1 shared publication- Hiroshi Mita
Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi, 329-0412, Japan
1 shared publication
Latest Publications
- 13 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation
Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.
- 13 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation
Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.
- Open Access
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Effects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses
Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses
Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.